No Data
US Stock MarketDetailed Quotes
ICVX Icosavax
Watchlist
10.120
-0.110-1.08% Close 11/30 16:00 ET
10.1200.0000.00%
Post 16:02 ET
10.820High9.750Low840.52KVolume
10.300Open10.230Pre Close8.65MTurnover2.87%Turnover RatioLossP/E (TTM)506.91MMarket Cap16.45052wk HighLossP/E (Static)50.09MShares3.12052wk Low2.18P/B296.62MFloat Cap49.990Historical High--Dividend TTM29.31MShs Float2.280Historical Low--Div YieldTTM10.46%Amplitude10.286Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Icosavax Company
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Single Segment582K100.00%
News
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. Shares of Ross Stores, Inc. (NASDAQ:ROST) surged during Friday's session as the company reported upbeat results fo
Guggenheim Initiates Coverage On Icosavax With Buy Rating, Announces Price Target of $28
Guggenheim analyst Seamus Fernandez initiates coverage on Icosavax with a Buy rating and announces Price Target of $28.
Icosavax Insiders Forfeit On 41% Gains After Selling Stock
While Icosavax, Inc. (NASDAQ:ICVX) shareholders have had a good week with the stock up 41%, insiders can't say the same having sold stock over the past year. The value of their investment would have
Comments
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--